Disease monitoring of patient with chronic heart failure

被引:6
作者
Nicholls, M. Gary [1 ]
Richards, A. Mark [1 ]
机构
[1] Christchurch Sch Med & Hlth Sci, Dept Med, Christchurch, New Zealand
关键词
D O I
10.1136/hrt.2005.078519
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Monitoring of patients with chronic heart failure requires recognition that "disease management programmes" for such patients need to be multifaceted with intensive patient education, optimisation of the therapeutic regimen and ongoing surveillance.2 6 20 In the absence of objective data, and since the various guidelines for managing patients with chronic heart failure do not provide uniform instructions, we have here given our personal view on what factors should be monitored, and how frequently. The vital question of optimisation of treatment is at present an uncertain goal wherein it is unclear whether drug doses should be directed according to completed trials or whether it is better to tailor treatment to some objective index of cardiac function in the individual patient. We declare our optimism regarding the place of BNP and NT-proBNP in individualising pharmacological treatment. The issue will become clear upon completion of several ongoing trials.
引用
收藏
页码:519 / 523
页数:5
相关论文
共 20 条
[11]   Preventable causative factors leading to hospital admission with decompensated heart failure [J].
Michalsen, A ;
König, G ;
Thimme, W .
HEART, 1998, 80 (05) :437-441
[12]   Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: Randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy [J].
Murdoch, DR ;
McDonagh, TA ;
Byrne, J ;
Blue, L ;
Farmer, R ;
Morton, JJ ;
Dargie, HJ .
AMERICAN HEART JOURNAL, 1999, 138 (06) :1126-1132
[13]   Relationship of current and past smoking to mortality and morbidity in patients with left ventricular dysfunction [J].
Suskin, N ;
Sheth, T ;
Negassa, A ;
Yusuf, S .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 37 (06) :1677-1682
[14]   Guidelines for the diagnosis and treatment of chronic heart failure:: executive summary (update 2005) [J].
Swedberg, K ;
Cleland, J ;
Dargie, H ;
Drexler, H ;
Follath, F ;
Komajda, M ;
Tavazzi, L ;
Smiseth, OA ;
Gavazzi, A ;
Haverich, A ;
Hoes, A ;
Jaarsma, T ;
Korewicki, J ;
Lévy, S ;
Linde, C ;
Lopez-Sendon, JL ;
Nieminen, MS ;
Piérard, L ;
Remme, WJ .
EUROPEAN HEART JOURNAL, 2005, 26 (11) :1115-1140
[15]   Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations [J].
Troughton, RW ;
Frampton, CM ;
Yandle, TG ;
Espiner, EA ;
Nicholls, MG ;
Richards, AM .
LANCET, 2000, 355 (9210) :1126-1130
[16]   Acute precipitants of congestive heart failure exacerbations [J].
Tsuyuki, RT ;
McKelvie, RS ;
Arnold, JMO ;
Avezum, A ;
Barretto, ACP ;
Carvalho, ACC ;
Isaac, DL ;
Kitching, AD ;
Piegas, LS ;
Teo, KK ;
Yusuf, S .
ARCHIVES OF INTERNAL MEDICINE, 2001, 161 (19) :2337-2342
[17]   Compliance in heart failure patients: the importance of knowledge and beliefs [J].
van der Wal, MHL ;
Jaarsma, T ;
Moser, DK ;
Veeger, NJGM ;
van Gilst, WH ;
van Veldhuisen, DJ .
EUROPEAN HEART JOURNAL, 2006, 27 (04) :434-440
[18]   Expanding indications for natriuretic peptides: Importance of better new (research) protocols [J].
Vasan, RS .
AMERICAN HEART JOURNAL, 2004, 148 (05) :743-746
[19]   Heritability and genetic linkage of plasma natriuretic peptide levels [J].
Wang, TJ ;
Larson, MG ;
Levy, D ;
Benjamin, EJ ;
Corey, D ;
Leip, EP ;
Vasan, RS .
CIRCULATION, 2003, 108 (01) :13-16
[20]   Disease management programmes for older people with heart failure: crucial characteristics which improve post-discharge outcomes [J].
Yu, DSF ;
Thompson, DR ;
Lee, DTF .
EUROPEAN HEART JOURNAL, 2006, 27 (05) :596-612